Serrapeptase is an enzyme that is produced in the intestines of silk worms to break down cocoon walls. This enzyme is proving to be a superior alternative to the non-steroidal anti-inflammatory agents (NSAIDs) traditionally used to treat rheumatoid arthritis and osteoarthritis. Its uses have also been extended to the treatment of chronic sinusitis and postoperative inflammation, and some preliminary research indicates that Serrapeptase may even help inhibit plaque build-up in arteries, thereby preventing atherosclerosis (hardening of the arteries) and a resulting heart attack or stroke. Therefore, much like aspirin, this naturally derived enzyme may work to prevent inflammation, pain, heart attack and stroke. Unlike aspirin and other over-the-counter (OTC) NSAIDs, Serrapeptase has not been shown to cause ulcers and stomach bleeding and also no inhibitory effects on prostaglandins and is devoid of gastrointestinal side effects.
Serrapeptase is thought to work in three ways:
1. It may reduce inflammation by thinning the fluids formed from injury, and facilitating the fluid drainage. This in turn, also speeds tissue repair.
2. It may help alleviate pain by inhibiting the release of pain-inducing amines called bradykinin.
3. It may enhance cardiovascular health by breaking down the protein by-products of blood coagulation called fibrin. Conveniently, Serrapeptase is able to dissolve the fibrin and other dead or damaged tissue without harming living tissue. This could enable the dissolution of atherosclerotic plaques without causing any harm to the inside of the arteries.
Serrapeptase has been used in Europe and Asia for over 25 years. Because the enzyme digests or dissolves all nonliving tissue, including blood clots, cysts and arterial plaque, it is used to treat a variety of conditions, including sprains and torn ligaments, postoperative swelling, venous thrombosis (clots in the legs), ear, nose and throat infections and atherosclerosis.
Medications blocking cholesterol biosynthesis hold the threat of liver, eye, lung and other soft tissue damage. While studies with Serrapeptase in the treatment of coronary artery disease are relatively new; some literature reports Serrapeptase as being superior to, and faster than, chelation.
Serrapeptase has been used to treat arterial blockage in coronary patients, with reports that Serrapeptase also dissolves blood clots, and causes varicose veins to shrink or diminish. Various clinic trials have shown that Serrapeptase digests non-living tissue, blood clots, cysts, arterial plaque and inflammation in all forms.
In clinical trials Serrapeptase has also shown to dramatically reduce the elasticity and viscosity of nasal mucus, thus helping people with sinus problems.
Indications shown in various studies and reported by Practitioners on their patients:
A Natural Anti-Inflammatory
Serrapeptase, also known as Serratia peptidase, is a proteolytic enzyme isolated from the non-pathogenic enterobacteria Serratia E15. When consumed in unprotected tablets or capsules, the enzyme is destroyed by acid in the stomach. However, enterically-coated tablets enable the enzyme to pass through the stomach unchanged, and be absorbed in the intestine. Serrapeptase is found in negligible amounts in the urine, suggesting that it is transported directly from the intestine into the bloodstream.
Clinical studies show that serrapeptase induces fibrinolytic, anti-inflammatory and anti-edemic (prevents swelling and fluid retention) activity in a number of tissues, and that its anti-inflammatory effects are superior to other proteolytic enzymes.
Besides reducing inflammation, one of serrapeptase's most profound benefits is reduction of pain, due to its ability to block the release of pain-inducing amines from inflamed tissues. In Germany and other European countries, serrapeptase is a common treatment for inflammatory and traumatic swellings, and much of the research that exists on this substance is of European origin. One double-blind study was conducted by German researchers to determine the effect of serrapeptase on post-operative swelling and pain. This study involved sixty-six patients who were treated surgically for fresh rupture of the lateral collateral ligament of the knee. On the third post-operative day, the group receiving serrapeptase exhibited a 50 percent reduction of swelling, compared to the controls. The patients receiving serrapeptase also became more rapidly pain-free than the controls, and by the tenth day, the pain had disappeared completely.
Serrapeptase and Sinusitis
Due to its inflammatory properties, serrapeptase has been shown in clinical studies to benefit chronic sinusitis sufferers. In this condition, the mucus in patients?nasal cavities is thickened and hypersecreted. This thickening causes mucus to be expelled less frequently. Japanese researchers evaluated the effects of serratiopeptidase (30 mg/day orally for four weeks) on the elasticity and viscosity of the nasal mucus in adult patients with chronic sinusitis. Serratiopeptidase reduced the viscosity of the mucus, improving the elimination of bronchopulmonary secretions.
Respiratory diseases are characterized by increased production of a more dense mucus modified in viscosity and elasticity. Traditionally, in respiratory diseases, muco-active drugs are prescribed to reestablish the physicochemical characteristics of the mucus in order to restore respiratory function. Some of these drugs, however, cause a functional depletion of mucus, whereas Serrapeptase alters the elasticity of mucus without depleting it. A powerful agent by itself, serrapeptase teamed with antibiotics delivers increased concentrations of the antimicrobial agent to the site of the infection. Bacteria often endure a process called biofilm formation, which results in resistance to antimicrobial agents. In an attempt to prevent this bacterial immunity, researchers have experimented with various means of inhibiting biofilm-embedded bacteria. Their search may have ended with serrapeptase. One study conducted by Italian researchers suggests that proteolytic enzymes could significantly enhance the activities of antibiotics against biofilms. Antibiotic susceptibility tests showed that serratiopeptidase greatly enhances the activity of the antibiotic, ofloxacin, and that it can inhibit biofilm formation.
Hans A. Nieper, M.D., an internist from Hannover, Germany, studied the effects of serrapeptase on plaque accumulations in the arteries. The formation of plaque involves deposits of fatty substances, cholesterol, cellular waste products, calcium and fibrin (a clotting material in the blood) on the inner lining of the arteries. Excessive plaque results in partial or complete blockage of the blood's flow through an artery, resulting in arteriosclerosis, or hardening of the arteries, and an ensuing stroke or heart attack. The evidence to support serrapeptase's role in preventing plaque build-up is anecdotal. Still, further studies are called for in this area as Nieper's research indicated that the protein-dissolving action of serrapeptase will gradually break down atherosclerotic plaques.
Cystic Breast Disease
Serrapeptase has also been used in the successful treatment of fibrocystic breast disease. In a double-blind study, 70 patients complaining of breast engorgement randomly were divided into a treatment group and a placebo group. Serrapeptase was superior to the placebo for improvement of breast pain, breast swelling and induration (firmness). 85.7 percent of the patients receiving serrapeptase reported moderate to marked improvement. No adverse reactions to serrapeptase were reported and the researchers concluded that "serrapeptase is a safe and effective method for the treatment of breast engorgement."
There are two main types of arthritis: Osteo-arthritis, which in lay terms is due to wear and tear of the joint and Rheumatoid arthritis which is a form of arthritis where the joints have become inflamed, possibly as a result of a virus or autoimmune response. In general Osteo-arthritic pain will respond faster to Serrapeptase treatment than rheumatoid arthritis that may need more intensive treatment
Serrapeptase helps immensely as it clears out all of the inflammation and dead/scar tissue. By clearing away this problem tissue it enables the bodies own healing system to replace it with healthy tissue. Serrapeptase is clearing the problem tissue and is treating the damage caused by the Arthritis - the condition itself must be treated with other measures such as nutrition etc.
Q: Will this conflict with any drugs I am taking or cause my blood to become to thin/strong?
A: There are many opinions about what to take with what and what is a so called 'blood thinner'.
Q: Has it any side effects or can I take too many?
A: No side effects have been found in over 25 years of studies and usage. Many people take very high doses to speed-up the relief e.g. in cases of sports injuries which can be as high as 30 per day with no side effects whatsoever except a faster recovery. It is even safe for children of 2 years+ for a wide range of conditions: (asthma, lung problems, arthritis, etc).
Q: What is the Clinical usage of Serrapeptase in children, with dosage precautions and other relevant clinical information?
A: It can be safely used with children. I recommend 1-3 tablets per day for children. If they cannot swallow the tablets, they can chew the tablet as it does not have any taste. (also capsules that can be broken open and mixed with honey). In fact a sore throat can be cleared in about 30 minutes by chewing 1-2 tablets. Our grandchildren use it when they get mucus problems from colds, with fast results.
1 capsule 3 times daily before food on an empty stomach and no food within an hour. Recommended to take 2 capsules 3 times daily for first 2 weeks.
Recommended to take 2 capsules 3 times daily for first 2 weeks.
|Bookmark This Page Print This Page Jump to Top Email Us|
|Email : firstname.lastname@example.org||Copyright © 2018 21st Century Nutrition. All Rights Reserved.|
|Home :: About Us :: Products :: Books :: Cosmetic & Toiletries :: Agents :: Miscellaneous :: Contact Us :: Links|